Provided by Tiger Trade Technology Pte. Ltd.

Sionna Therapeutics

7.62
+0.14001.87%
Pre-market: 7.49-0.1300-1.71%04:00 EDT
Volume:1.22M
Turnover:9.17M
Market Cap:342.89M
PE:-3.51
High:7.75
Open:7.40
Low:7.12
Close:7.48
52wk High:54.97
52wk Low:4.01
Shares:45.00M
Float Shares:16.73M
Volume Ratio:1.13
T/O Rate:7.31%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.1683
EPS(LYR):-1.8835
ROE:-32.34%
ROA:-21.54%
PB:1.29
PE(LYR):-4.05

Loading ...

Sionna Therapeutics upgraded to Sector Perform from Underperform at RBC Capital

TIPRANKS
·
Aug 10

Sionna Therapeutics, Inc. : RBC Raises to Sector Perform from Underperform; Cuts Target Price to $5 from $23

THOMSON REUTERS
·
Aug 10

Tenax, Sionna Shares Sink After Trial Failures

Dow Jones
·
Aug 10

Wedbush Downgrades Sionna Therapeutics to Neutral From Outperform, Adjusts PT to $5 From $53

MT Newswires Live
·
Aug 10

Sionna Therapeutics Shares Down 91% After Co's Experimental Drug Misses Mid-Stage Trial Goal

THOMSON REUTERS
·
Aug 10

Sector Update: Healthcare Stocks Edge Higher Premarket Monday

MT Newswires Live
·
Aug 10

Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Monday Amid Rising Oil Prices

MT Newswires Live
·
Aug 10

Sionna Shares Tumble After Cystic-Fibrosis Treatment Unexpectedly Misses Endpoint

Dow Jones
·
Aug 10

Sionna Scraps Genetic Disorder Drug Program After Trial Setback; Shares Tank

Reuters
·
Aug 10

U.S. Stocks on the MOVE-Apple, Barrick Mining, AbCellera Biologics

Reuters
·
Aug 10

Top Premarket Decliners

MT Newswires Live
·
Aug 10

Sionna Falls After Experimental Drug Misses Mid-Stage Trial Goal

Reuters
·
Aug 10

Sionna Therapeutics Says SION-719 Phase 2a Trial Misses Sweat Chloride Endpoint in Cystic Fibrosis

Reuters
·
Aug 10

Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update

THOMSON REUTERS
·
Aug 10

Sionna Therapeutics, - Evaluating Sion-719 Trial Confounders to Inform Sion-451 Program Next Steps

THOMSON REUTERS
·
Aug 10

Sionna Therapeutics, - Ends Q2 with $268.30 Mln in Cash; Plans Capital Preservation Actions

THOMSON REUTERS
·
Aug 10

Sionna Therapeutics, - Sion-719 Phase 2a Trial Does not Meet Key Endpoint; Program Discontinued as Add-on

THOMSON REUTERS
·
Aug 10

RBC Capital Remains a Sell on Sionna Therapeutics, Inc. (SION)

TIPRANKS
·
Aug 08

Sionna Therapeutics is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 08

Sionna Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06